announced today the discontinuation of its Phase 2 clinical study, FIRCE-1, for the treatment of large B-cell lymphoma (LBCL). According to InvestingPro analysis, the company's stock appears ...

The artificial intelligence (AI) revolution began more than two years ago with the debut of ChatGPT in November 2022. Since ...

Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market ...

In this article, we are going to take a look at where Conduit Pharmaceuticals Inc. (NASDAQ:CDT) stands against the other AI ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year ... 14.7% after 13 weeks in a relatively small phase 2 trial. Viking continued to impress ...

Cloudflare is capitalizing on the developer moat that it has built over the past few years. Click here to find out why I rate NET stock a Hold.

Artificial intelligence has been the driving force behind the stock market’s gains since late 2022. The debut of ChatGPT that ...

According to Bank of America, several companies are prime candidates for a stock split in the near future, which could lead to shares doubling the average market return, if historical trends are any ...

the second-largest stock on the market, further extreme melt-ups in its price will seemingly become increasingly difficult. However, CEO Jensen Huang says the next phase of AI’s growth will be ...